129722-25-4

Basic information

• Product Name: DEHYDRO ARIPIPRAZOLE
• Synonyms: DEHYDRO ARIPIPRAZOLE;7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]Butoxy]-2(1H)-Quinolinone;2(1H)-Quinolinone,7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-;7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2(1H)-one;Aripiprazole Related CoMpound G;Aripiprazole USP impurity G(EP impurity E);Dehydro aripiprazole solution;Aripiprazole Related Compound G (25 mg) (7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}quinolin-2(1H)-one)
• CAS NO: 129722-25-4
• Molecular Formula: C₂₃H₂₅Cl₂N₃O₂
• Molecular Weight: 446.37
• Mol File: 129722-25-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 654.375 °C at 760 mmHg
• Flash Point: 349℃
• Appearance: /
• Density: 1.282 g/cm³
• Storage Temp.: ?20°C
• Solubility: Chloroform (Slightly), Methanol (Slightly, Heated)
• PKA: 11.22±0.70(Predicted)
• CAS DataBase Reference: DEHYDRO ARIPIPRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: DEHYDRO ARIPIPRAZOLE(129722-25-4)
• EPA Substance Registry System: DEHYDRO ARIPIPRAZOLE(129722-25-4)

Safety Data

• Hazard Codes: F,T
• Statements: 11-23/24/25-39/23/24/25-52/53
• Safety Statements: 16-36/37-45-61
• RIDADR: UN 3286 8(6.1)(3) / PGII
• WGK Germany: 1
• Hazardous Substances Data: 129722-25-4(Hazardous Substances Data)

Usage

Uses

Dehydro Aripiprazole (Aripiprazole EP Impurity E; Aripiprazole USP Related Compound G) is an impurity of Aripiprazole (A771000), a selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity.

General Description

Dehydro Aripiprazole is the primary, active metabolite of aripiprazole, marketed as the atypical antipsychotic Abilify? for the treatment of schizophrenia, bipolar disorder, and clinical depression. This new certified solution standard is suitable for use in LC or GC applications including forensic or clinical toxicology analysis and urine drug testing.

Upstream product

• 119532-26-2 1-(2,3-dichlorophenyl)-piperazine hydrochloride 
• 203395-59-9 7–(4-bromobutoxy)quinolin-2(1H)-one 
• 70500-72-0 7-hydroxy-1H-quinolin-2-one 
• 129722-12-9 aripiprazole 
• 41202-77-1 1-(2,3-dichlorophenyl)piperazine 

Downstream Products

• 1026778-41-5 Aripiprazole hydrochloride 
• 1352726-47-6 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2-yl dibenzylcarbamate 
• 1352726-51-2 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2-yl pivalate 
• 1352726-46-5 N,N-diethyl-7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxamide 
• 1352726-45-4 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2-yl diethylcarbamate 

Relevant articles and documents

Polymorphism of dehydro-aripiprazole, the active metabolite of the antipsychotic drug aripiprazole (abilify)

Crystal form exploration of dehydro-aripiprazole (dAPZ), the active metabolite of the antipsychotic drug aripiprazole (APZ), elucidated five polymorphs (I, II, III, IV, and V), two methanol solvates, and a monohydrate. The forms were characterized by ther

Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists

Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side

3,4-DIHYDRO-2 (1H) - QUINOLINONE AND 2 (1H)-QUINOLINONE DERIVATIVES

The present invention relates to novel 3,4-dihydro-2(lH)-quinolinone and 2(lH)-quinolinone derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by atypical antipsychotic agents. The invention further provides methods for using a compound of this invention to determine concentrations of a corresponding 3,4-dihydro-2(lH)- quinolinone or 2(lH)-quinolinone compound, particularly in biological fluids, and to determine metabolism patterns of that 3,4-dihydro-2(lH)-quinolinone or 2(1H)-quinolinone compound.